A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study.
Cancer
; 121(19): 3465-71, 2015 Oct 01.
Article
in En
| MEDLINE
| ID: mdl-26079295
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Non-Hodgkin
/
Sirolimus
/
Bortezomib
Type of study:
Incidence_studies
/
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
/
Male
Country/Region as subject:
America do norte
Language:
En
Journal:
Cancer
Year:
2015
Document type:
Article
Country of publication: